Argatroban

Clinical Management of Argatroban in Patients With Heparin Induced Thrombocytopenia Type II

Study on Safety and Effectiveness of Three Doses of Argatroban as Anticoagulant in Percutaneous Coronary Intervention (PCI)

Safety of Argatroban Infusion in Conduction Disturbances

Multi-arm Optimization of Stroke Thrombolysis

Safety and Feasibility of Argatroban As Anticoagulant in Adults with ECMO

Safety and Efficacy of Argatroban Applicated in Anticoagulation of V-V ECMO

Anticoagulation in Critically Ill Patients With COVID-19 (The IMPACT Trial)

Efficacy Argatroban in Ischemic Stroke With Early Deterioration (EASE)

A Phase I Study of the Co-administration of VLX-1005 and Argatroban in Healthy Human Subjects

Open-Label, Randomised, Active Controlled, Multi-Centre Phase 3 Study Safety and Efficacy of Danaparoid vs Argatroban

Argatroban Plus R-tPA for Acute Ischemic Stroke

Thromboprophylaxis After Surgery for Gynecologic Malignancy in China

Argatroban in Critically Ill Patients With Heparin Resistance

Retrospective Registry of Patients With Acute Heparin-induced Thrombocytopenia Type II

Safety and Feasibility of Argatroban, Tissue Plasminogen Activator and Intra-arterial Therapy in Stroke

Argatroban for Preventing Occlusion and Restenosis After Intracranial and Extracranial Artery Stenting

Argatroban for Preventing Occlusion and Restenosis After Extracranial Vertebral Artery Stenting

Argatroban Stroke Treatment - A Pilot Safety Study

Argatroban Versus Lepirudin in Critically Ill Patients

Efficacy and Safety Study of Argatroban to Treat Heparin-Induced Thrombocytopenia